PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<table>
<thead>
<tr>
<th>(51) International Patent Classification</th>
<th>(11) International Publication Number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A61K 31/415, C07D 233/84</td>
<td>WO 89/06128</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(21) International Application Number:</th>
<th>(13) International Publication Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCT/US88/04579</td>
<td>13 July 1989 (13.07.89)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(22) International Filing Date:</th>
<th>(43) Priority Application Number:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(31) Priority Application Number:</th>
<th>(32) Priority Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>29 December 1987 (29.12.87)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(33) Priority Country:</th>
<th>(74) Designated States:</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>AU, DK, JP</td>
</tr>
</tbody>
</table>

| (71) Applicant: SMITHKLINE BECKMAN CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US). |
| (72) Inventors: KRUSE, Lawrence, Ivan; 33 Firs Walk, Tewin, Hertfordshire AL6 0NY (GB). ROSS, Stephen, Torey; 718 Old State Road, Berwyn, PA 19312 (US). OHLSTEIN, Eliot, Howard; 61 Justin Drive, Plymouth Valley, PA 19401 (US). |

| (54) Title: 2-CARBOXYALKYLTTHIOIMIDAZOLES AND ESTERS THEREOF AS DOPAMINE-ß-HYDROXYLASE INHIBITORS |
| (57) Abstract |

Potent dopamine-ß-hydroxylase inhibitors having formula (I), that are useful to inhibit dopamine-ß-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-ß-hydroxylase activity in mammals.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
</tr>
<tr>
<td>DE</td>
<td>Germany, Federal Republic of</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
</tr>
<tr>
<td>GB</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>IT</td>
<td>Italy</td>
</tr>
<tr>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
</tr>
<tr>
<td>KR</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>LK</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>SU</td>
<td>Soviet Union</td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
</tr>
</tbody>
</table>
2-CARBOXYALKYLTHIOIMIDAZOLES AND ESTERS THEREOF AS
DOPAMINE-β-HYDROXYLASE INHIBITORS

FIELD OF THE INVENTION

This invention relates to novel compounds that inhibit dopamine-β-hydroxylase.

BACKGROUND OF THE INVENTION

In the catecholamine biosynthetic pathway, tyrosine is converted in three steps to norepinephrine (NE). Intermediates are dihydroxyphenylalanine (DOPA) and dopamine (DA). Dopamine is hydroxylated to norepinephrine by dopamine-β-hydroxylase (DBH) in the presence of oxygen and ascorbic acid.

Inhibition of catecholamine activity decreases blood pressure. Weinshilboum, Mayo Clin. Proc. 55, 39 (1980), reviews compounds that inhibit catecholamine activity by acting upon adrenergic receptors. Alternatively, the catecholamine biosynthetic pathway can be suppressed at any of the three steps, resulting in reduced NE levels. In addition to producing an antihypertensive effect, inhibitors of NE synthesis are active as diuretics, natriuretics, cardiotonics, and vasodilators. Inhibition of DBH activity can have the added advantage of increasing DA levels, which as reported by Ehrreich et al., "New Antihypertensive Drugs," Spectrum Publishing, 1976, pp. 409-432, has selective vasodilator activity at certain concentrations.
DBH inhibitors also have been shown to reduce or prevent formation of gastric ulcers in rats by Hidaka et al., "Catecholamine and Stress," edit. by Usdin et al., Pergamon Press, Oxford, 1976, pp. 159-165 and by Osumi et al., Japan J. Pharmacol. 23, 904 (1973).

A number of DBH inhibitors are known. These generally are divided into two classes, namely, metal chelating agents, which bind copper in the enzyme, and phenethylnalamine analogues. Rosenberg et al., "Essays in Neurochemistry and Neuropharmacology," Vol. 4, ed. by Youdim et al., John Wiley & Sons, 1980, pp. 179-192, and Goldstein, Pharmacol. Rev. 18(1), 77 (1966), review DBH inhibitors. The former report that many potent DBH inhibitors have a hydrophobic side chain of size comparable to the aromatic ring of DA, leading the authors to suggest that incorporation of a terminal hydroxyl group on a 4- to 6- carbon side chain on a phenethylnalamine analogue may yield potent inhibitors.

Known DBH inhibitors include:


(b) BRL 8242 [See Claxton et al., Eur. J. Pharmacol. 37, 179 (1976)];

(c) 1-alkylimidazole-2-thiols [See, Hanlon et al., Life Sci. 12, 417 (1973); Fuller et al., Adv. Enzyme Regul. 15, 267 (1976)];

(d) substituted thioureas [See, Johnson et al., J. Pharmacol. Exp. Ther. 168, 229 (1969)]; and

All the above compounds except benzylxoyamine and benzylhydrazine apparently owe their inhibitory effect to metal chelating properties. Alkyl derivatives of imidazole-2-thiol are more potent, presumably due to non-specific interaction of the alkyl substituent with the enzyme. Benzylxoyamine and benzylhydrazine are phenethylalamine analogues which apparently act as competitive inhibitors.

In addition to the above compounds, Runti et al., Il Farmaco Ed. Sci. 36, 260 (1980), report that other fusaric acid derivatives and analogues inhibit DBH. These include phenylpicolinic acid, which has twice the inhibitory activity of fusaric acid, and 5-(4-chlorobutyl) picolinic acid, and others such as substituted amides of fusaric acid and acids and amides of 5-butyroylpicolinic acid, 5-aminopicolinic acid and 5-hydrazinopicolinic acid, and derivatives thereof.

Hidaka et al., Molecular Pharmacology, 9, 172-177 (1972) report that 5-(3,4-dibromobutyl)picolinic acid and 5-(dimethyldithiocarbamoylmethyl)picolinic acid are DBH inhibitors.

Bupicomide, 5-(n-butyl)picolinamidine, is reported by Ehrreich et al., "New Antihypertensive Drugs", Spectrum Publications, 1976, pg. 409-432, to be a DBH inhibitor that has antihypertensive activity.

In European Patent Application No. 125,033 (published November 14, 1984) a series of 1-phenyl and 1-phenylalkylimidazole compounds having a mercapto or alkylthio group in the 2-position are disclosed. These compounds are described as having DBH inhibiting activity.

United States Patent No. 4,487,761 describes several methylpyridine derivatives isolated from the fermentation broth of a strain of Streptoverticillium. These compounds inhibit DBH activity.
United States Patent No. 4,532,331 describes various 1-benzyl-2-aminomethylimidazole derivatives that inhibit DBH activity and includes pharmaceutical compositions containing these derivatives and methods of using these derivatives to inhibit DBH activity.

Non-specific, often toxic effects to known DBH inhibitors have obviated clinical use of these compounds. Fusaric acid, for example, is hepatotoxic. See, for example, Teresawa et al., Japan. Circ. J., 35, 339 (1971) and references cited therein. Presumably, the picolinic acid structure interacts with a number of metalloproteins and enzymes non-specifically to produce the observed side effects.

Iverson, Acta Chem. Scand. 21, 279 (1967) reports compounds having the formula:

![Chemical Structure](image)

wherein R can be -CO₂H or -CH₂NHC₆H₅, but does not report pharmaceutical uses for the compounds.

In neoprene rubber vulcanization mixtures, 1,3-dihydro-4-phenyl-2H-imidazole-2-thione has been used as a vulcanization accelerator. Elastomers 92:165013u (1980).

**SUMMARY OF THE INVENTION**

The present invention resides in the discovery that DBH is inhibited by substituted 2-carboxy-alkythio-1-aralkylimidazoles, and the C₁₄ alkyl ester derivatives thereof. These compounds are potent long acting DBH inhibitors.
The presently preferred compound of the invention and the compound included in the pharmaceutical compositions and used in the methods of the invention is 2-(carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole.

The invention also is a method of inhibiting DBH activity in mammals, including humans, which comprises administering internally to a subject an effective amount of a substituted 2-carboxyalkythio-1-arylalkylimidazole, or a C₁₋₄ alkyl ester derivative thereof.

Included in the present invention are pharmaceutical compositions comprising compounds useful in the method of the invention and a pharmaceutical carrier.

**DETAILED DESCRIPTION OF THE INVENTION**

The presently invented compounds that inhibit DBH have the following formula:

![Chemical Structure]

\[ \text{in which:} \]

- \( X \) is H, F, Cl, Br, I, C₁₋₄ alkyl, CN, NO₂, SO₂NH₂, COOH, OH, CHO, C₁₋₄ alkoxy, CH₂OH, CH₂OC₁₋₄ alkyl, CF₃, C₂F₅, C₃F₇, SO₂CH₃, SO₂CF₃, or CO₂C₆H₄₂a+1 wherein \( a \) is 1-5, or any accessible combination thereof of up to 5 substituents;

- \( n \) is 0-5;
- \( m \) is 1-5;
- \( R \) is H or C₁₋₄ alkyl; or
- any pharmaceutically acceptable salt or hydrate thereof.
As used herein, "accessible combination thereof" means any combination of the substituents on the phenyl moiety that is available by chemical synthesis and is stable. C<sub>1-4</sub>alkyl means a straight or branched chain alkyl having from 1 to 4 carbons.

Formula (I) compounds are prepared from corresponding phenylalkyl-2-mercaptopimidazoles by processes such as shown in Scheme I, below. The starting phenylalkyl-2-mercaptopimidazoles are prepared from corresponding benzaldehydes or phenylalkylaldehydes by known processes such as shown in Scheme II, below, and described in European Patent Specification 125,033, published November 14, 1984. In Scheme I, m and n are as described in Formula (I), X<sup>1</sup> is X as in Formula (I) except OH, and Z is bromo, chloro, fluoro, or iodo.
Scheme I

(a)

\[ \text{Base} \]

(b)

\[ \text{Z(\(CH_2\))}_m \text{-CO}_2\text{R} \]
According to Scheme I, when a compound (b), a
Formula (I) compound in which R is H, is the desired end
product, a compound (a) and a haloalkanoic acid,
preferably, chloro, are added to a mixture of a suitable
solvent, preferably dimethyl formamide and water, and two
molar equivalents of a base such as triethylamine, sodium
hydroxide, potassium carbonate, or, preferably, potassium
hydroxide to yield a compound (b), as illustrated in
Example 1.

When Formula (I) compounds in which R is
C\textsubscript{1-4}alkyl are desired the haloalkyl acid, above, is
replaced by a haloalkanoate ester such as in Example 9,
below. The S-alkylation conditions employed are similar
to those used for the carboxylic acids, with the exception
that a single molar equivalent of strong base is
required. These product carboxylate esters obviously may
also serve as intermediates for the carboxylic acids
themselves by subjecting the esters to mild hydrolytic
conditions using either aqueous acid, for example aqueous
hydrochloric acid or, preferably, aqueous base, for
example aqueous sodium hydroxide. In the latter case, the
final product is obtained by neutralizing the hydrolysate
with aqueous acid, as in Example 10.

Formula (I) compounds in which X is OH are
prepared from a compound (b) in which X\textasciitilde is C\textsubscript{1-4}alkoxy
using known hydrolysis methods, for example by treatment
with boron tribromide or hydrogen bromide in an
appropriate solvent as exemplified in Example 2.

The phenylalkyl-2-mercaptoimidazoles used as
starting materials in Scheme I are prepared from
corresponding benzanaldheydes or phenylalkylnaldehydes using
known processes such as shown in Scheme II below. The
starting benzanaldheydes and phenylalkylnaldehydes are known
and can be synthesized according to published procedures
or can be obtained readily from various commercial
suppliers. In Scheme II, X\textasciitilde is X as in Formula (I)
except OH, n' is 1-5, and q is 0-4.
SCHEME II

(c) \[ \text{NH}_2\text{CH}_2\text{CH(OC}_{1-4}\text{alkyl})_2 \] →

(d) \[ \text{NCH}_2\text{CH(OC}_{1-4}\text{alkyl})_2 \] → Reduction

(e) \[ \text{H}_2\text{O}/\text{SCN}^- \] →

(a')
According to Scheme II, a compound (c) in a suitable organic solvent is reacted with an aminoacetaldehyde diC<sub>1-4</sub>alkylacetal to yield a compound (d). Thereafter, catalytic hydrogenation of a compound (d) using a suitable catalyst, preferably palladium on carbon, or reduction of a compound (d) using a suitable reducing agent such as sodium borohydride, lithium aluminum hydride, or aluminum hydride yields a compound (e). Reaction of a compound (e) with an acidic solution of a thiocyanate salt, preferably potassium thiocyanate in hydrochloric acid, yields a compound (a') which is a Scheme I compound (a) in which n is 1-5.

Formula (I) compounds in which n is 0 are synthesized from corresponding phenylimidazoles which are prepared by known processes such as reaction of an appropriately substituted phenyl isothiocyanate with an aminoacetaldehyde diC<sub>1-4</sub>alkylacetal followed by strong acid catalyzed cyclization, as illustrated in Example 8, below.

Pharmaceutically acceptable acid addition salts of compounds of Formula I in which R is C<sub>1-4</sub>alkyl are formed with appropriate organic or inorganic acids by methods known in the art. For example, the base is reacted with a suitable inorganic or organic acid in an aqueous miscible solvent such as ethanol with isolation of the salt by removing the solvent or in an aqueous immiscible solvent when the acid is soluble therein, such as ethyl ether or chloroform, with the desired salt separating directly or isolated by removing the solvent. Exemplary of the salts which are included in this invention are maleate, fumarate, lactate, oxalate, methanesulfonate, ethanesulfonate, benzenesulfonate, tartrate, citrate, hydrochloride, hydrobromide, sulfate, phosphate, quinate, and nitrate salts.
Pharmaceutically acceptable base addition salts of compounds of Formula I in which R is H are prepared by known methods from organic and inorganic bases include nontoxic alkali metal and alkaline earth bases, for example, calcium, sodium, and potassium hydroxide; ammonium hydroxide, and nontoxic organic bases such as triethylamine, butylamine, piperazine, and (trihydroxymethyl)methylamine.

Because the Formula (I) compounds inhibit DBH activity, they are useful as diuretic, natriuretic, cardiotonic, antihypertensive, and vasodilator agents, as well as antiulcerogenic and anti-Parkinsonian agents.

Listed in Table I are Formula (I) compounds that were tested for *in vitro* DBH inhibition by a standard procedure for assaying conversion of tyramine to octopamine in the presence of DBH. J. J. Pisano, *et al.*, *Biochim. Biophys. Acta*, 43, 566-568 (1960). Octopamine was assayed following sodium periodate oxidation to p-hydroxybenzaldehyde by measuring spectrophotometric absorbance at 330 nm. Inhibition is given in molar concentration of compound at which DBH activity was halved (IC$_{50}$). Fusaric acid, by this test, has an IC$_{50}$ of 8 $\times$ 10$^{-7}$M; 2-(carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole has an IC$_{50}$ of 4.2 $\times$ 10$^{-2}$M.

Spontaneously hypertensive rats were treated with 2-(carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole at a dose of 50 mg/kg intraperitoneally, and mean arterial blood pressure was monitored for four hours using an indwelling cannula in the femoral artery. When compared to vehicle-treated controls, the animals treated with this compound exhibited significant blood pressure reductions within 30 minutes following treatment and remained significantly reduced for 4 hours. The maximal blood pressure reduction was approximately 43 mmHg.
Formula (I) compounds are incorporated into convenient pharmaceutical dosage forms such as capsules, tablets, or liquids for ingestion, injection, or inhalation. Solid or liquid pharmaceutical carriers can be employed. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any material used to give prolonged release of the active compound, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit.

When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid, or an aqueous or nonaqueous liquid suspension.

The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating and compressing, when necessary, for tablet forms, or mixing, filling, and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.

Doses of the present compounds of Formula (I) in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity selected from the range of 0.1–100 mg/kg of active compound, preferably 0.1–50 mg/kg. The selected dose is administered to a human patient in need of DBH inhibition from 1–6 times daily, orally, rectally, by injection, by inhalation, or continuously by infusion. Oral dosage units for human administration preferably contain from 1 to 500 mg of active compound. Parenteral administration, which uses lower dosages is preferred. Oral administration, at higher dosages, however, also can be used when safe and convenient for the patient.
The method of this invention of inhibiting DBH activity in mammals, including humans, comprises administering internally to a subject an effective DBH inhibiting amount of a Formula (I) compound.

The method of this invention of reducing blood pressure in mammals, including humans, comprises administering internally to a subject an effective amount of a Formula (I) compound.

The following examples are illustrative of preparation of Formula (I) compounds. The examples are not intended to limit the scope of the invention as defined hereinabove and as claimed below.

**EXAMPLE 1**

2-((Carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole
1-(3,5-Difluorobenzyl)-2-mercaptoimidazole

(2.26 g, 0.010 mole) and chloroacetic acid (0.95 g, 0.010 mole) were dissolved in a mixture of dimethylformamide (10 ml) and water (0.5 ml), and potassium hydroxide (1.12 g, 0.020 mole) in water (10 ml) was added dropwise with stirring at ambient temperature over 30 minutes. Stirring at ambient temperature was continued for five hours. The solution was then diluted with water (10 ml) and acidified with concentrated hydrochloric acid. A trace of precipitate formed. The mixture was filtered and the pH of the filtrate was adjusted to 5.5 with concentrated ammonium hydroxide and the mixture was extracted with three portions of methylene chloride. Concentration of the combined extracts gave a clear, heavy oil which was triturated with boiling ether. A white crystalline solid formed which was filtered and recrystallized from ethyl acetate–hexane to give 1.18 g (42% yield) of 2-((carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole, mp 101-103°C.
EXAMPLE 2

2-(Carboxymethylthio)-1-(4-hydroxybenzyl)imidazole

The Example 1 process wherein
1-(3,4-difluorobenzyl)-2-mercaptoimidazole is replaced by
1-(4-methoxybenzyl)-2-mercaptoimidazole yields
2-(carboxymethylthio)-1-(4-methoxybenzyl)imidazole.

Treatment of this compound in methylene chloride with
boron tribromide yields 2-(carboxymethylthio)-1-(4-
hydroxybenzyl)imidazole.

EXAMPLE 3

2-(Carboxymethylthio)-1-(phenylbutyl)imidazole

The Example 1 procedure wherein 1-(3,5-
difluorobenzyl)-2-mercaptoimidazole is replaced by
1-(1-phenylbutyl)-2-mercaptoimidazole yields
2-(carboxymethylthio)-1-(1-phenylbutyl)imidazole.

EXAMPLE 4

2-(Carboxymethylthio)-1-(3,5-difluoro-
4-methoxybenzyl)imidazole

The Example 1 process wherein 1-(3,5-
difluorobenzyl)-2-mercaptoimidazole is replaced by
1-(3,5-difluoro-4-methoxybenzyl)-2-mercaptoimidazole
yields 2-(carboxymethylthio)-1-(3,5-difluoro-4-
methoxybenzyl)imidazole.

EXAMPLE 5

2-(Carboxymethylthio)-1-(2,4,6-trichloro-3-
methoxy-5-trifluoromethylbenzyl)imidazole

The Example 1 procedure wherein 1-(3,5-
difluorobenzyl)-2-mercaptoimidazole is replaced by
1-(2,4,5-trichloro-3-methoxy-5-trifluoromethylbenzyl)-
2-mercaptoimidazole yields 2-(carboxymethylthio)-1-(2,4,5-
trichloro-3-methoxy-5-trifluoromethylbenzyl)imidazole.
EXAMPLE 6

2-((Carboxymethylthio)-1-(4-cyanobenzyl)imidazole

The Example 1 process wherein 1-(3,5-difluorobenzyl)-2-mercaptoimidazole is replaced by 1-(4-cyanobenzyl)-2-mercaptoimidazole yields 2-((carboxymethylthio)-1-(4-cyanobenzyl)imidazole.

EXAMPLE 7

2-((Carboxymethylthio)-1-(4-nitrobenzyl)imidazole

The Example 1 process wherein 1-(3,5-difluorobenzyl)-2-mercaptoimidazole is replaced by 1-(4-nitrobenzyl)-2-mercaptoimidazole yields 2-((carboxymethylthio)-1-(4-nitrobenzyl)imidazole.

EXAMPLE 8

2-((Carboxymethylthio)-1-(4-methoxyphenyl)imidazole

A solution of 10 g (0.06 mole) of p-methoxyphenyl isothiocyanate in 100 ml of chloroform was treated with 6.3 g (0.06 mole) of aminoacetaldehyde dimethyl acetal. The solvent was evaporated and the residue was recrystallized from ethanol to yield N-(p-methoxyphenyl)-N'-(β,β-dimethoxyethyl)thiourea, 9.2 g (57%). A suspension of this thiourea in a solution of 5 ml of concentrated sulfuric acid and 20 ml of water was refluxed for 3 hours. The mixture was cooled and a solid was filtered, washed with water, and dried. Recrystallization from ethanol gave 1-(4-methoxyphenyl)-2-mercaptoimidazole, 4.9 g (70%), mp 215-217°C.

The Example 1 procedure wherein 1-(3,5-difluorobenzyl)-2-mercaptoimidazole is replaced by 1-(4-methoxyphenyl)-2-mercaptoimidazole yields 2-((carboxymethylthio)-1-(4-methoxyphenyl)imidazole.
EXAMPLE 9

2-(2-Carbomethoxyethylthio)-1-(3,5-difluorobenzyl)imidazole

1-(3,5-Difluorobenzyl)-2-mercaptoimidazole

(2.26 g, 0.010 mole) and potassium hydroxide (0.56 g, 0.010 mole) in dimethylformamide (10 ml) containing water (0.5 ml) are stirred under argon at ambient temperature and methyl-3-bromo propionate (1.67 g, 0.010 mole) is added in one portion. The reaction mixture is heated at 95°C for sixteen hours, cooled and extracted three times with ether. The combined ether extracts are concentrated to give an oil. This is purified by flash chromatography on silica gel eluting with methanol in methylene chloride to give 2-(2-carbomethoxyethylthio)-1-(3,5 difluorobenzyl)imidazole.

EXAMPLE 10

2-(2-Carboxyethylthio)-1-(3,5-difluorobenzyl)imidazole

2-(2-Carbomethoxyethylthio)-1-(3,5-difluorobenzyl)-imidazole (3.12, 0.010 mole) is stirred with 2.5 N aqueous sodium hydroxide (20 ml) and the reaction mixture is heated at reflux for one hour and then cooled and neutralized with concentrated hydrochloric acid. The mixture is then extracted three times with ether and the combine ether extracts are concentrated. A crystalline solid is obtained by trituration of the residue with boiling hexane. This is recrystallized from ethyl acetate–hexane to give 2-(2-carboxyethylthio)-1-(3,5-difluorobenzyl)imidazole.

EXAMPLE 11

An oral dosage form for administering the presently invented compounds is produced by screening, mixing, and filling into hard gelatin capsules the ingredients in the proportions shown in Table I, below.
Table I

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Amounts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-(Carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole</td>
<td>50 mg</td>
</tr>
<tr>
<td>magnesium stearate</td>
<td>5 mg</td>
</tr>
<tr>
<td>lactose</td>
<td>75 mg</td>
</tr>
</tbody>
</table>

Example 12

The sucrose, calcium sulfate dihydrate, and Formula (I) compound shown in Table II below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened, and compressed into a tablet.

Table II

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Amounts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-(Carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole</td>
<td>100 mg</td>
</tr>
<tr>
<td>calcium sulfate dihydrate</td>
<td>150 mg</td>
</tr>
<tr>
<td>sucrose</td>
<td>20 mg</td>
</tr>
<tr>
<td>starch</td>
<td>10 mg</td>
</tr>
<tr>
<td>talc</td>
<td>5 mg</td>
</tr>
<tr>
<td>stearic acid</td>
<td>3 mg</td>
</tr>
</tbody>
</table>

Example 13

2-(Carboxymethylthio)-1-(3,5-difluorobenzyl)-imidazole dihydrochloride, 75 mg, is dispersed in 25 ml of normal saline to prepare an injectable preparation.
Contemplated equivalents of Formula (I) compounds are compounds that upon administration to mammals, including humans, are metabolized to Formula (I) compounds or metabolized to any Formula (I) compound active metabolites at a sufficient rate and in sufficient amounts to produce physiologic activity of Formula (I) compounds. Such compounds also would be included in the invented pharmaceutical compositions and used in the invented methods.

While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.
What is claimed is:

1. A compound of the formula:

\[
\begin{array}{c}
\text{X} \\
\text{(CH}_2\text{)}_n \\
\text{S- (CH}_2\text{)}_m \text{-CO}_2\text{R}
\end{array}
\]

in which:

\[
\begin{align*}
X &\text{ is } H, F, Cl, Br, I, C_{1-4}\text{ alkyl, CN, NO}_2, \text{ SO}_2\text{NH}_2, \text{ COOH, OH, CHO, C}_{1-4}\text{ alkoxy, CH}_2\text{OH, CH}_2\text{OC}_{1-4}\text{ alkyl, CF}_3, \text{ C}_2\text{F}_5, \text{ C}_3\text{F}_7, \text{ SO}_2\text{CH}_3, \\
\text{SO}_2\text{CF}_3, \text{ or CO}_2\text{C}_a\text{H}_{2a+1} \text{ wherein } a \text{ is } 1-5, \text{ or any accessible combination thereof of up to 5 substituents:}
\end{align*}
\]

\[
\begin{align*}
n &\text{ is } 0-5; \\
m &\text{ is } 1-5; \\
R &\text{ is } H \text{ or } C_{1-4} \text{ alkyl; or a pharmaceutically acceptable salt or hydrate thereof.}
\end{align*}
\]

2. A compound of Claim 1 wherein n is 1.

3. A compound of Claim 2 wherein m is 1.

4. A compound of Claim 3 wherein R is H.

5. A compound of Claim 4 that is 2-(carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole.


7. A pharmaceutical composition of Claim 6 wherein the compound is 2-(carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole.

9. A method of Claim 8 wherein the compound is
2-(carboxymethylthio)-1-(3,5-difluorobenzyl)imidazole.

10. A method of reducing blood pressure in
mammals that comprises administering an effective amount
of a compound of Claim 1.
INTERNATIONAL SEARCH REPORT

I. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(4): A61K 31/415; C07D 233/84
U.S.C1. 514/398; 548/337

II. FIELDS SEARCHED

<table>
<thead>
<tr>
<th>Classification System</th>
<th>Classification Symbols</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>514/398; 548/337</td>
</tr>
</tbody>
</table>

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.

III. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, ((A, B, C, D, \ldots)) with indication, where appropriate, of the relevant passages</th>
<th>Relevant to Claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>U.S., A, 3,334,112 (WRIGHT ET AL). published 1 August 1967, see column 1, first formula.</td>
<td>1-7</td>
</tr>
</tbody>
</table>

* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Q" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search: 14 FEBRUARY 1989

Date of Mailing of this International Search Report: 17 APR 1989

Signature of Authorized Officer: RICHARD A. SCHNAPF